Announcement on Provision for Asset Impairment for 2025
Filed with SSE · · 6 pages · Chinese
Shanghai Haohai Biological Technology Co., Ltd. on 6ix
Earlier from Shanghai Haohai Biological Technology
- Announcement on Voluntary Disclosure of the Wholly-owned Subsidiary’s Intraocular Crosslinked Sodium Hyaluronate Gel Product Obtaining the Medical Device Registration Certificate
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Shareholding Reduction Plan for Shareholders
- Indicative Announcement on Cancellation of Repurchased H-shares and the Passive Equity Change of Controlling Shareholder, Actual Controller and Its Persons Acting in Concert Reaching 1% Scale
- Announcement on Receipt of the Decision for Administrative Penalty by One of the Company’s Controlling Shareholders and Actual Controllers Due to Non-company-related Matters
Later from Shanghai Haohai Biological Technology
- Announcement on Voluntary Disclosure of the Wholly-owned Subsidiary’s Multifocal Aspherical Intraocular Lens Product Obtaining the Medical Device Registration Certificate
- Report for Q1 2026
- Notice on Convening the 2025 Annual General Meeting, the 1st Shareholders' Meeting of A Shares of 2026 and the 1st Shareholders' Meeting of H Shares of 2026
- Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
- Announcement on Result of Shareholding Reduction by Shareholder
Follow Shanghai Haohai Biological Technology into a list and get an email when it puts out news.
Follow Shanghai Haohai Biological Technology